The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 12 2021
Historique:
received: 06 05 2021
revised: 04 07 2021
accepted: 02 09 2021
pubmed: 10 9 2021
medline: 15 1 2022
entrez: 9 9 2021
Statut: ppublish

Résumé

Nucleoside analogues form the backbone of many therapeutic regimens in oncology and require the presence of intracellular enzymes for their activation. A ProTide is comprised of a nucleoside fused to a protective phosphoramidate cap. ProTides are easily incorporated into cells whereupon the cap is cleaved and a preactivated nucleoside released. 3'-Deoxyadenosine (3'-dA) is a naturally occurring adenosine analogue with established anticancer activity We describe the synthesis of NUC-7738. We determine the IC We show that NUC-7738 overcomes the cancer resistance mechanisms that limit the activity of 3'-dA and that its activation is dependent on ProTide cleavage by the enzyme histidine triad nucleotide-binding protein 1. PK and tumor samples obtained from the ongoing first-in-human phase I clinical trial of NUC-7738 further validate our Our study provides proof that NUC-7738 overcomes cellular resistance mechanisms and supports its further clinical evaluation as a novel cancer treatment within the growing pantheon of anticancer ProTides.

Identifiants

pubmed: 34497073
pii: 1078-0432.CCR-21-1652
doi: 10.1158/1078-0432.CCR-21-1652
pmc: PMC9401491
doi:

Substances chimiques

Nucleosides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

6500-6513

Subventions

Organisme : Wellcome Trust
ID : 203141/Z/16/Z
Pays : United Kingdom

Commentaires et corrections

Type : CommentOn

Informations de copyright

©2021 The Authors; Published by the American Association for Cancer Research.

Références

Cell Cycle. 2015;14(5):761-71
pubmed: 25590866
Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):31-5
pubmed: 10887642
Antimicrob Agents Chemother. 2014;58(4):1943-51
pubmed: 24419340
J Pharm Pharmacol. 2005 Dec;57(12):1509-19
pubmed: 16354395
Proc Natl Acad Sci U S A. 1970 Dec;67(4):1878-85
pubmed: 5275385
Mol Med Rep. 2019 Feb;19(2):901-908
pubmed: 30535479
Science. 2013 Apr 26;340(6131):479-83
pubmed: 23519211
Arch Pathol Lab Med. 2014 May;138(5):595-601
pubmed: 24236805
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
Br J Cancer. 2018 Oct;119(7):815-822
pubmed: 30206366
Sci Rep. 2019 May 21;9(1):7643
pubmed: 31113993
Cancer Chemother Pharmacol. 2020 Jun;85(6):1011-1014
pubmed: 32476108
Sci Rep. 2019 Mar 18;9(1):4696
pubmed: 30886197
Cell Death Discov. 2018 May 23;4:62
pubmed: 29844932
Nat Methods. 2013 Oct;10(10):965-71
pubmed: 24161985
Life Sci. 2013 Nov 26;93(23):863-9
pubmed: 24121015
Oncogene. 2011 Apr 7;30(14):1615-30
pubmed: 21170083
Curr Protoc Nucleic Acid Chem. 2013 Jun;Chapter 15:15.5.1-15.5.15
pubmed: 23775807
RNA. 2012 Dec;18(12):2236-50
pubmed: 23118416
Sci Rep. 2019 Oct 31;9(1):15760
pubmed: 31673018
J Med Chem. 2011 Oct 27;54(20):7247-58
pubmed: 21892829
Med Oncol. 2020 Jun 11;37(7):61
pubmed: 32529264
Trends Biochem Sci. 2004 Feb;29(2):72-9
pubmed: 15102433
Onco Targets Ther. 2018 Aug 01;11:4479-4490
pubmed: 30122940
Cancer Res. 1977 Oct;37(10):3824-33
pubmed: 332340
Int J Oncol. 2013 Mar;42(3):1036-44
pubmed: 23292300
Future Oncol. 2020 Jun;16(16):1069-1081
pubmed: 32374623
J Med Chem. 2014 Feb 27;57(4):1531-42
pubmed: 24471998
Pharmacol Res Perspect. 2015 Mar;3(2):e00121
pubmed: 26038697
Genome Res. 2014 Dec;24(12):2059-65
pubmed: 25373145
Nat Rev Drug Discov. 2009 Jan;8(1):33-40
pubmed: 19116625
J Mol Model. 2020 Jan 17;26(2):29
pubmed: 31953681
J Agric Food Chem. 2010 Apr 28;58(8):4638-43
pubmed: 20302371
Phytochemistry. 2008 May;69(7):1469-95
pubmed: 18343466
Science. 2009 Nov 27;326(5957):1231-5
pubmed: 19965467
Toxicol Appl Pharmacol. 1997 Nov;147(1):39-45
pubmed: 9356305
Nucleosides Nucleotides Nucleic Acids. 2007;26(8-9):1121-4
pubmed: 18058549
Oncol Lett. 2015 Aug;10(2):595-599
pubmed: 26622539
Biochem Pharmacol. 2011 Sep 1;82(5):441-52
pubmed: 21658373
Int J Mol Sci. 2018 Oct 04;19(10):
pubmed: 30287757
Cell Death Dis. 2020 Mar 30;11(3):210
pubmed: 32231206
J Pharm Sci. 2012 Oct;101(10):3979-88
pubmed: 22833171
R Soc Open Sci. 2018 Dec 19;5(12):181247
pubmed: 30662735
Nature. 1950 Dec 2;166(4231):949
pubmed: 14796634
Cell Chem Biol. 2020 Feb 20;27(2):214-222.e4
pubmed: 31991096
Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000109
pubmed: 20516126
Cell Death Differ. 2001 Jun;8(6):621-30
pubmed: 11536013

Auteurs

Hagen Schwenzer (H)

Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Erica De Zan (E)

Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Mustafa Elshani (M)

School of Medicine, University of St Andrews, St. Andrews, United Kingdom.

Ruud van Stiphout (R)

Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Mary Kudsy (M)

School of Medicine, University of St Andrews, St. Andrews, United Kingdom.

Josephine Morris (J)

Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Valentina Ferrari (V)

School of Pharmacy and Pharmaceutical Sciences, University of Cardiff, Cardiff, United Kingdom.

In Hwa Um (IH)

School of Medicine, University of St Andrews, St. Andrews, United Kingdom.

James Chettle (J)

Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Farasat Kazmi (F)

Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Leticia Campo (L)

Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Alistair Easton (A)

Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Sebastian Nijman (S)

Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Michaela Serpi (M)

School of Pharmacy and Pharmaceutical Sciences, University of Cardiff, Cardiff, United Kingdom.

Stefan Symeonides (S)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom.

Ruth Plummer (R)

Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

David J Harrison (DJ)

School of Medicine, University of St Andrews, St. Andrews, United Kingdom.
NuCana PLC, Edinburgh, United Kingdom.

Gareth Bond (G)

Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Sarah P Blagden (SP)

Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom. sarah.blagden@oncology.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH